377 related articles for article (PubMed ID: 25979595)
1. A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies.
Rini B; Goddard A; Knezevic D; Maddala T; Zhou M; Aydin H; Campbell S; Elson P; Koscielny S; Lopatin M; Svedman C; Martini JF; Williams JA; Verkarre V; Radulescu C; Neuzillet Y; Hemmerlé I; Timsit MO; Tsiatis AC; Bonham M; Lebret T; Mejean A; Escudier B
Lancet Oncol; 2015 Jun; 16(6):676-85. PubMed ID: 25979595
[TBL] [Abstract][Full Text] [Related]
2. Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project).
Brookman-May S; May M; Shariat SF; Xylinas E; Stief C; Zigeuner R; Chromecki T; Burger M; Wieland WF; Cindolo L; Schips L; De Cobelli O; Rocco B; De Nunzio C; Feciche B; Truss M; Gilfrich C; Pahernik S; Hohenfellner M; Zastrow S; Wirth MP; Novara G; Carini M; Minervini A; Simeone C; Antonelli A; Mirone V; Longo N; Simonato A; Carmignani G; Ficarra V;
Eur Urol; 2013 Sep; 64(3):472-7. PubMed ID: 22748912
[TBL] [Abstract][Full Text] [Related]
3. A Multigene Signature Based on Cell Cycle Proliferation Improves Prediction of Mortality Within 5 Yr of Radical Nephrectomy for Renal Cell Carcinoma.
Morgan TM; Mehra R; Tiemeny P; Wolf JS; Wu S; Sangale Z; Brawer M; Stone S; Wu CL; Feldman AS
Eur Urol; 2018 May; 73(5):763-769. PubMed ID: 29249291
[TBL] [Abstract][Full Text] [Related]
4. Validation of serum C-reactive protein (CRP) as an independent prognostic factor for disease-free survival in patients with localised renal cell carcinoma (RCC).
de Martino M; Klatte T; Seemann C; Waldert M; Haitel A; Schatzl G; Remzi M; Weibl P
BJU Int; 2013 Jun; 111(8):E348-53. PubMed ID: 23495750
[TBL] [Abstract][Full Text] [Related]
5. External validation of the Leibovich prognosis score for nonmetastatic clear cell renal cell carcinoma at a single European center applying routine pathology.
Pichler M; Hutterer GC; Chromecki TF; Jesche J; Kampel-Kettner K; Rehak P; Pummer K; Zigeuner R
J Urol; 2011 Nov; 186(5):1773-7. PubMed ID: 21944989
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-11 receptor predicts post-operative clinical outcome in patients with early-stage clear-cell renal cell carcinoma.
Pan D; Xu L; Liu H; Zhang W; Zhu Y; Xu J; Gu J
Jpn J Clin Oncol; 2015 Feb; 45(2):202-9. PubMed ID: 25420690
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of single-nucleotide polymorphism signature for recurrence in localised renal cell carcinoma: a retrospective analysis and multicentre validation study.
Wei JH; Feng ZH; Cao Y; Zhao HW; Chen ZH; Liao B; Wang Q; Han H; Zhang J; Xu YZ; Li B; Wu JT; Qu GM; Wang GP; Liu C; Xue W; Liu Q; Lu J; Li CX; Li PX; Zhang ZL; Yao HH; Pan YH; Chen WF; Xie D; Shi L; Gao ZL; Huang YR; Zhou FJ; Wang SG; Liu ZP; Chen W; Luo JH
Lancet Oncol; 2019 Apr; 20(4):591-600. PubMed ID: 30880070
[TBL] [Abstract][Full Text] [Related]
8. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ;
BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Value of a Long Non-coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma.
Qu L; Wang ZL; Chen Q; Li YM; He HW; Hsieh JJ; Xue S; Wu ZJ; Liu B; Tang H; Xu XF; Xu F; Wang J; Bao Y; Wang AB; Wang D; Yi XM; Zhou ZK; Shi CJ; Zhong K; Sheng ZC; Zhou YL; Jiang J; Chu XY; He J; Ge JP; Zhang ZY; Zhou WQ; Chen C; Yang JH; Sun YH; Wang LH
Eur Urol; 2018 Dec; 74(6):756-763. PubMed ID: 30143382
[TBL] [Abstract][Full Text] [Related]
10. p21-activated kinase 1 predicts recurrence and survival in patients with non-metastatic clear cell renal cell carcinoma.
Zhu Y; Xu L; An H; Liu W; Wang Z; Xu J
Int J Urol; 2015 May; 22(5):447-53. PubMed ID: 25711487
[TBL] [Abstract][Full Text] [Related]
11. Validation of the 12-gene colon cancer recurrence score as a predictor of recurrence risk in stage II and III rectal cancer patients.
Reimers MS; Kuppen PJ; Lee M; Lopatin M; Tezcan H; Putter H; Clark-Langone K; Liefers GJ; Shak S; van de Velde CJ
J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25261968
[TBL] [Abstract][Full Text] [Related]
12. Multimodal recurrence scoring system for prediction of clear cell renal cell carcinoma outcome: a discovery and validation study.
Gui CP; Chen YH; Zhao HW; Cao JZ; Liu TJ; Xiong SW; Yu YF; Liao B; Cao Y; Li JY; Huang KB; Han H; Zhang ZL; Chen WF; Jiang ZY; Gao Y; Han GP; Tang Q; Ouyang K; Qu GM; Wu JT; Guo JP; Li CX; Li PX; Liu ZP; Hsieh JT; Cai MY; Li XS; Wei JH; Luo JH
Lancet Digit Health; 2023 Aug; 5(8):e515-e524. PubMed ID: 37393162
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological features of recurrence after radical surgery for nonmetastatic renal cell carcinoma.
Ishimura T; Sakai I; Harada K; Hara I; Eto H; Miyake H
Int J Clin Oncol; 2004 Oct; 9(5):369-72. PubMed ID: 15549586
[TBL] [Abstract][Full Text] [Related]
14. The Presence of Vascular Mimicry Predicts High Risk of Clear Cell Renal Cell Carcinoma after Radical Nephrectomy.
Zhou L; Chang Y; Xu L; Liu Z; Fu Q; Yang Y; Lin Z; Xu J
J Urol; 2016 Aug; 196(2):335-42. PubMed ID: 26970566
[TBL] [Abstract][Full Text] [Related]
15. External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology.
Zigeuner R; Hutterer G; Chromecki T; Imamovic A; Kampel-Kettner K; Rehak P; Langner C; Pummer K
Eur Urol; 2010 Jan; 57(1):102-9. PubMed ID: 19062157
[TBL] [Abstract][Full Text] [Related]
16. The influence of pNx/pN0 grouping in a multivariate setting for outcome modeling in patients with clear cell renal cell carcinoma.
Ward JF; Blute ML; Cheville JC; Lohse CM; Weaver AL; Zincke H
J Urol; 2002 Jul; 168(1):56-60. PubMed ID: 12050492
[TBL] [Abstract][Full Text] [Related]
17. The key role of time in predicting progression-free survival in patients with renal cell carcinoma treated with partial or radical nephrectomy: conditional survival analysis.
Abdollah F; Suardi N; Capitanio U; Matloob R; Fossati N; Castiglione F; Di Trapani E; Di Trapani D; Russo A; Carenzi C; Montorsi F; Rigatti P; Bertini R
Urol Oncol; 2014 Jan; 32(1):43.e9-16. PubMed ID: 23911684
[TBL] [Abstract][Full Text] [Related]
18. Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study.
Schutz FA; Pomerantz MM; Gray KP; Atkins MB; Rosenberg JE; Hirsch MS; McDermott DF; Lampron ME; Lee GS; Signoretti S; Kantoff PW; Freedman ML; Choueiri TK
Lancet Oncol; 2013 Jan; 14(1):81-7. PubMed ID: 23219378
[TBL] [Abstract][Full Text] [Related]
19. Management and extended outcome of patients with synchronous bilateral solid renal neoplasms in the absence of von Hippel-Lindau disease.
Blute ML; Amling CL; Bryant SC; Zincke H
Mayo Clin Proc; 2000 Oct; 75(10):1020-6. PubMed ID: 11040850
[TBL] [Abstract][Full Text] [Related]
20. The effect of bilaterality, pathological features and surgical outcome in nonhereditary renal cell carcinoma.
Blute ML; Itano NB; Cheville JC; Weaver AL; Lohse CM; Zincke H
J Urol; 2003 Apr; 169(4):1276-81. PubMed ID: 12629342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
